Sionna Therapeutics, Inc. (SION)
2.825
-0.14
(-4.88%)
USD |
NASDAQ |
Nov 20, 16:00
2.82
0.00 (0.00%)
After-Hours: 20:00
Sionna Therapeutics Research and Development Expense (TTM) : 74.32M for Sept. 30, 2026
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 74.32M |
| June 30, 2026 | 72.04M |
| March 31, 2026 | 65.56M |
| December 31, 2025 | 60.26M |
| September 30, 2025 | 59.35M |
| Date | Value |
|---|---|
| June 30, 2025 | 67.89M |
| March 31, 2025 | 60.74M |
| December 31, 2024 | 57.29M |
| September 30, 2024 | 52.92M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Capricor Therapeutics, Inc. | 107.50M |
| ARS Pharmaceuticals, Inc. | 30.74M |
| Ardelyx, Inc. | 91.28M |
| Compass Therapeutics, Inc. | 68.60M |
| ACADIA Pharmaceuticals, Inc. | 319.46M |